Benjamin F Cravatt

This inventor holds 31 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Chemical Biology. Top assignees: Scripps Research Institute, Abide Therapeutics, Inc., Vividion Therapeutics, Inc.. Active years: 1995-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benjamin F Cravatt. Retrieved from https://idiyas.com/inventor/benjamin-f-cravatt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 31 (Patent Applications = 14)

% Patents Active = 80.6

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 6 (Patent Applications = 14)

Average Co-Inventor Count = 4.2

ph-index = 8

Forward Citations = 280(Granted Patents)

Location History:

San Diego, CA (US) (1995 - 2024)
La Jolla, CA (US) (2001 - 2024)

Company Filing History:

31 out of 1,208

Scripps Research Institute

patents

5 out of 18

Abide Therapeutics, Inc.

patents

3 out of 5

Vividion Therapeutics, Inc.

Lundbeck La Jolla Research Center, Inc.

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

Areas of Expertise:

Carbamate Compounds

Serine Hydrolase

Cereblon Modulators

Lipid Probes

Cysteine-Reactive Ligands

Protein Degradation

Fatty-Acid Amide

Inhibitors

Photoreactive Ligands

Neurobehaviors

Enzyme Regulation

Proteomic Analysis

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12018004 - Carbamate compounds and methods of making and using same (2024-06-25),

2. 11897865 - ABHD12 inhibitors and methods of making and using same (2024-02-13),

3. 11771689 - Cereblon modulators and uses thereof (2023-10-03),

4. 11691984 - Compounds and methods for DCAF-mediated protein degradation (2023-07-04),

5. 11535597 - Photoreactive ligands and uses thereof (2022-12-27),

6. 11530189 - Carbamate compounds and methods of making and using same (2022-12-20),

7. 11021453 - Carbamate compounds and methods of making and using same (2021-06-01),

8. 10869860 - Cereblon modulators and uses thereof (2020-12-22),

9. 10859585 - Lipid probes and uses thereof (2020-12-08),

10. 10782295 - Cysteine-reactive ligand discovery in proteomes (2020-09-22),

11. 10781239 - In vivo engineered cereblon protein (2020-09-22),

12. 10670605 - Cysteine reactive probes and uses thereof (2020-06-02),

13. 10583137 - Triazole DAGLα inhibitors (2020-03-10),

14. 10168342 - Lipid probes and uses thereof (2019-01-01),

15. 9981972 - N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets (2018-05-29),

Title: The Innovative Journey of Benjamin F. Cravatt

Introduction: Benjamin F. Cravatt is a renowned inventor based in La Jolla, California, known for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Benjamin F. Cravatt holds several patents in the areas of drug discovery, enzyme activity modulation, and proteomics, showcasing his continuous innovation in the industry.

Career Highlights: With a distinguished career spanning over two decades, Cravatt has held key research positions at leading institutions, driving forward cutting-edge research in biochemistry and chemical biology.

Collaborations: Throughout his career, Benjamin F. Cravatt has collaborated with top researchers, pharmaceutical companies, and academic institutions globally, fostering a culture of innovation and knowledge exchange.

Conclusion: Benjamin F. Cravatt's relentless pursuit of innovation and his commitment to advancing the field of biotechnology make him a true pioneer in the industry.

Profile summary based on public USPTO records.